Painceptor Pharma Corp. Raises $24.4 M Series B Investment Round
MONTREAL, March 6 /CNW Telbec/ - PainCeptor Pharma Corp., a
pharmaceutical company focused on the development of novel therapeutics for
the treatment of chronic and acute pain, today announced it has raised $24.4 M
in a Series B investment round. Investors in this round include: Desjardins
Venture Capital, CDP Capital (managed by VantagePoint Venture Partners),
T2C2/Bio 2000, Business Development Bank of Canada, and Lothian Partners
27 (sarl) SICAR. To date, PainCeptor has raised a cumulative total of $47 M in
venture capital funding.